Cargando…

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

The effects of sorafenib – an oral multikinase inhibitor targeting the tumour and tumour vasculature – were evaluated in patients with advanced melanoma enrolled in a large multidisease Phase II randomised discontinuation trial (RDT). Enrolled patients received a 12-week run-in of sorafenib 400 mg t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eisen, T, Ahmad, T, Flaherty, K T, Gore, M, Kaye, S, Marais, R, Gibbens, I, Hackett, S, James, M, Schuchter, L M, Nathanson, K L, Xia, C, Simantov, R, Schwartz, B, Poulin-Costello, M, O'Dwyer, P J, Ratain, M J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2006
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360687/ https://www.ncbi.nlm.nih.gov/pubmed/16880785 http://dx.doi.org/10.1038/sj.bjc.6603291

Ejemplares similares

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
por: Eisen, T, et al.
Publicado: (2011)

Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel
por: Jilaveanu, Lucia B., et al.
Publicado: (2013)

Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial
por: Rothermundt, C, et al.
Publicado: (2006)

Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours
por: Jones, Robin L., et al.
Publicado: (2019)

A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma
por: Larkin, J M G, et al.
Publicado: (2007)

Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia
por: Langabeer, Stephen E., et al.
Publicado: (2020)

Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma
por: Waters, J S, et al.
Publicado: (2004)

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma
por: Larkin, J M G, et al.
Publicado: (2010)

Renal cell carcinoma and the use of sorafenib
por: Larkin, James MG, et al.
Publicado: (2006)

Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response
por: Zhang, Yingqiang, et al.
Publicado: (2015)

Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma
por: Bae, Heewon, et al.
Publicado: (2023)

A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer
por: Harries, M, et al.
Publicado: (2004)

Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels
por: Smalley, K S M, et al.
Publicado: (2007)

Accelerated Disease Progression after Discontinuation of Sorafenib in a Patient with Metastatic Papillary Thyroid Cancer
por: Yun, Kyung-Jin, et al.
Publicado: (2014)

A targeted approach to reducing rates of discontinuation and dose reduction in patients receiving sorafenib or regorafenib
por: Nix, Ryan, et al.
Publicado: (2019)

Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma
por: Rangwala, Reshma, et al.
Publicado: (2014)

Discontinuous and non-discontinuous subgenomic RNA transcription in a nidovirus
por: van Vliet, A.L.W., et al.
Publicado: (2002)

Sorafenib Dose Escalation is Not Uniformly Associated with Blood Pressure Elevations in Normotensive Patients with Advanced Malignancies
por: Karovic, Sanja, et al.
Publicado: (2014)

Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
por: Pécuchet, N, et al.
Publicado: (2012)

Bursts in discontinuous Aeolian saltation
por: Carneiro, M. V., et al.
Publicado: (2015)

The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis
por: Pope, Janet E, et al.
Publicado: (2014)

A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma
por: Morris, S L, et al.
Publicado: (2004)

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
por: Ikeda, M., et al.
Publicado: (2016)

Sustained complete response of hepatocellular carcinoma with portal vein tumor thrombus following discontinuation of sorafenib: A case report
por: SHIOZAWA, KAZUE, et al.
Publicado: (2014)

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
por: Handolias, D, et al.
Publicado: (2010)

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
por: Schwartz, G K, et al.
Publicado: (2011)

Lithium-associated hypothyroidism: Reversible after lithium discontinuation?
por: Lieber, I., et al.
Publicado: (2021)

Quasi-Isotropic and Pseudo-Ductile Highly Aligned Discontinuous Fibre Composites Manufactured with the HiPerDiF (High Performance Discontinuous Fibre) Technology
por: Longana, M. L., et al.
Publicado: (2019)

Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE
por: Papp, K.A., et al.
Publicado: (2015)

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)
por: Papp, KA, et al.
Publicado: (2015)

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
por: Wattenberg, Max M., et al.
Publicado: (2019)

Discontinuities in the electromagnetic field
por: Idemen, M Mithat
Publicado: (2011)

Sorafenib in Dupuytren and Ledderhose Disease
por: Schoenfeld, Joshua D, et al.
Publicado: (2022)

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib
por: El Dika, Imane, et al.
Publicado: (2020)

Why do patients discontinue fertility treatment? A systematic review of reasons and predictors of discontinuation in fertility treatment
por: Gameiro, S., et al.
Publicado: (2012)

The emerging role of respiratory physiotherapy: A profile of the attitudes of nurses and physicians in Saudi Arabia
por: Al Mohammedali, Zainab, et al.
Publicado: (2016)

Ambient air pollutant concentrations and asthma-related hospital admissions during COVID-19 transport restrictions
por: Kelly, C., et al.
Publicado: (2022)

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
por: Killestein, J., et al.
Publicado: (2014)

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
por: Procopio, G, et al.
Publicado: (2011)

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer
por: Eisen, T, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_42rqbqeq6esoriqj6g9ah4tlfp